175 related articles for article (PubMed ID: 25372945)
1. Validation of Bmi1 as a therapeutic target of hepatocellular carcinoma in mice.
Qi S; Li B; Yang T; Liu Y; Cao S; He X; Zhang P; Li L; Xu C
Int J Mol Sci; 2014 Nov; 15(11):20004-21. PubMed ID: 25372945
[TBL] [Abstract][Full Text] [Related]
2. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma.
Chiba T; Miyagi S; Saraya A; Aoki R; Seki A; Morita Y; Yonemitsu Y; Yokosuka O; Taniguchi H; Nakauchi H; Iwama A
Cancer Res; 2008 Oct; 68(19):7742-9. PubMed ID: 18829528
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of Bmi1 inhibits bladder cancer cell growth both in vitro and in vivo by blocking cell cycle at G1 phase and inducing apoptosis.
Luo HB; Li B; Yuan WG; Xu CR
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):730-735. PubMed ID: 26489630
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules.
Yang T; Chen Y; Zhao P; Xue H; You J; Li B; Liu Y; He C; Zhang X; Fan L; Lee RJ; Li L; Ma X; Xu C; Xiang G
Nanomedicine; 2018 Oct; 14(7):2009-2021. PubMed ID: 29842934
[TBL] [Abstract][Full Text] [Related]
5. Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis.
Xu CR; Lee S; Ho C; Bommi P; Huang SA; Cheung ST; Dimri GP; Chen X
Mol Cancer Res; 2009 Dec; 7(12):1937-45. PubMed ID: 19934271
[TBL] [Abstract][Full Text] [Related]
6. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
7. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1.
Wu WR; Sun H; Zhang R; Yu XH; Shi XD; Zhu MS; Zeng H; Yan LX; Xu LB; Liu C
Oncotarget; 2016 Apr; 7(14):18684-93. PubMed ID: 26919246
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells.
Zhu D; Wan X; Huang H; Chen X; Liang W; Zhao F; Lin T; Han J; Xie W
Oncol Rep; 2014 Feb; 31(2):727-36. PubMed ID: 24337040
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.
Bartucci M; Hussein MS; Huselid E; Flaherty K; Patrizii M; Laddha SV; Kui C; Bigos RA; Gilleran JA; El Ansary MMS; Awad MAM; Kimball SD; Augeri DJ; Sabaawy HE
Target Oncol; 2017 Aug; 12(4):449-462. PubMed ID: 28589491
[TBL] [Abstract][Full Text] [Related]
10. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice.
Chiba T; Seki A; Aoki R; Ichikawa H; Negishi M; Miyagi S; Oguro H; Saraya A; Kamiya A; Nakauchi H; Yokosuka O; Iwama A
Hepatology; 2010 Sep; 52(3):1111-23. PubMed ID: 20648475
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
12. Bmi1 drives hepatocarcinogenesis by repressing the TGFβ2/SMAD signalling axis.
Li B; Chen Y; Wang F; Guo J; Fu W; Li M; Zheng Q; Liu Y; Fan L; Li L; Xu C
Oncogene; 2020 Jan; 39(5):1063-1079. PubMed ID: 31591477
[TBL] [Abstract][Full Text] [Related]
13. Down regulation of miR200c promotes radiation-induced thymic lymphoma by targeting BMI1.
Cui J; Cheng Y; Zhang P; Sun M; Gao F; Liu C; Cai J
J Cell Biochem; 2014 Jun; 115(6):1033-42. PubMed ID: 24375660
[TBL] [Abstract][Full Text] [Related]
14. Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil.
Zhang R; Xu LB; Yue XJ; Yu XH; Wang J; Liu C
Oncol Rep; 2013 Mar; 29(3):967-74. PubMed ID: 23242307
[TBL] [Abstract][Full Text] [Related]
15. Bmi1 is required for hepatic progenitor cell expansion and liver tumor development.
Fan L; Xu C; Wang C; Tao J; Ho C; Jiang L; Gui B; Huang S; Evert M; Calvisi DF; Chen X
PLoS One; 2012; 7(9):e46472. PubMed ID: 23029524
[TBL] [Abstract][Full Text] [Related]
16. [PRODUCT OF THE BMI1--A KEY COMPONENT OF POLYCOMB--POSITIVELY REGULATES ADIPOCYTE DIFFERENTIATION OF MOUSE MESENCHYMAL STEM CELLS].
Petrov NS; Vereschagina NA; Sushilova EN; Kropotov AV; Miheeva NF; Popov BV
Tsitologiia; 2016; 58(2):83-90. PubMed ID: 27228653
[TBL] [Abstract][Full Text] [Related]
17. Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression.
Guo J; Deng N; Xu Y; Li L; Kuang D; Li M; Li X; Xu Z; Xiang M; Xu C
Pharmacol Res; 2021 Feb; 164():105365. PubMed ID: 33307220
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid
Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G
Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257
[TBL] [Abstract][Full Text] [Related]
19. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma.
Wang R; Fan H; Sun M; Lv Z; Yi W
Technol Cancer Res Treat; 2022; 21():15330338211070689. PubMed ID: 35072573
[TBL] [Abstract][Full Text] [Related]
20. Bmi1 knockdown inhibits hepatocarcinogenesis.
Ruan ZP; Xu R; Lv Y; Tian T; Wang WJ; Guo H; Nan KJ
Int J Oncol; 2013 Jan; 42(1):261-8. PubMed ID: 23138990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
